Celcuity Inc. (CELC)
CELC moved a median of +0.13% 30 minutes after news, and -0.32% by the close. How CELC actually reacts to news — the realized, point-in-time move the market made, measured across 354 labeled events over the last three years with zero look-ahead.
CELC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 343 |
| 30-min | +0.13% | 52% | 353 |
| 60-min | +0.08% | 53% | 354 |
| to close | -0.32% | 47% | 344 |
| Middle 50% of CELC reactions | -0.91% to +1.33% |
|---|---|
| Median reaction (30-min) | +0.13% |
| Measured reactions | 354 |
Half of all Celcuity Inc. news events land between -0.91% and +1.33% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CELC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 31 | +0.46% | 55% | +0.13% |
| Rating reiterations | 92 | -0.17% | 41% | -0.59% |
| Price-target raises | 12 | +0.01% | 50% | +0.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CELC ranks against every other measured name →
That’s how CELC usually reacts — get an email when it moves on news →Email me when CELC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CELC's baseline. Nothing else.
Recent CELC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | +0.78% | +1.25% | |
| Celcuity Appoints David Gryska To Its Board Of Directors | Press release | GlobeNewswire | -0.39% | -4.03% | |
| Form 8-K Celcuity Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | -4.03% | |
| Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States | Press release | GlobeNewswire | +4.05% | -2.76% | |
| Form 8-K Celcuity Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +4.05% | -2.76% | |
| Celcuity To Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.71% | +3.35% | |
| Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer | Press release | GlobeNewswire | -0.88% | +2.92% | |
| Form 8-K Celcuity Inc. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | +2.92% | |
| Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +7.88% | +10.79% | |
| Form 10-Q Celcuity Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.88% | +10.79% | |
| Form 8-K Celcuity Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +7.88% | +10.79% | |
| Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call | Press release | GlobeNewswire | -1.02% | +0.35% | |
| CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law | Press release | PR Newswire | -1.23% | +3.01% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -1.23% | +3.01% | |
| CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -1.23% | +3.01% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Celcuity Inc. (CELC) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.55% | -0.78% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.23% | +3.06% | |
| Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer | Press release | GlobeNewswire | -0.11% | +3.07% | |
| Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.19% | -1.09% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.57% | -3.49% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.27% | -1.08% | |
| Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.07% | +2.57% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.59% | -1.85% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +2.15% | -0.67% | |
| Form 8-K Celcuity Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -2.64% | -3.48% | |
| Form 8-K/A Celcuity Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | -2.02% | |
| Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer | Press release | GlobeNewswire | -2.64% | -3.48% | |
| Form 8-K Celcuity Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +5.43% | |
| Form 305B2 Celcuity Inc. | SEC filing · Form 305B2 | SEC EDGAR | -2.76% | -4.53% | |
| Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 | Press release | GlobeNewswire | -0.90% | +4.20% | |
| Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 | Press release | GlobeNewswire | +6.40% | +3.42% | |
| Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advan | Press release | GlobeNewswire | +2.35% | -3.77% | |
| Form 8-K Celcuity Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | -3.77% | |
| Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026 | Press release | GlobeNewswire | -1.75% | -7.00% | |
| Celcuity To Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.60% | -2.28% | |
| Form 8-K/A Celcuity Inc. For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +7.01% | |
| Form 8-K Celcuity Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | +0.12% | |
| Form S-8 Celcuity Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.18% | +0.12% | |
| Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.50% | +5.75% | |
| Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients | Press release | GlobeNewswire | +1.52% | +7.42% | |
| Form 10-Q Celcuity Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.50% | +5.75% | |
| Form 8-K Celcuity Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +5.75% | |
| Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call | Press release | GlobeNewswire | -2.37% | -4.89% | |
| Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort | Press release | GlobeNewswire | -0.81% | +3.06% | |
| Form 8-K Celcuity Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | +3.06% | |
| Form ARS Celcuity Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.45% | +1.49% | |
| Form DEF 14A Celcuity Inc. For: Apr 02 | SEC filing · Form DEF | SEC EDGAR | +0.45% | +1.49% | |
| Form DEFA14A Celcuity Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.45% | +1.49% | |
| Form 10-K Celcuity Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.26% | +5.09% | |
| Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.26% | +5.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CELC section they belong to.
Where else CELC is measured.
CELC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Aurora Cannabis Inc. - Common Shares (ACB) | 354 | -0.18% | 47% |
| Avid Bioservices, Inc. (CDMO) | 354 | 0.00% | 49% |
| AnaptysBio, Inc. (ANAB) | 344 | -0.51% | 44% |
| REGENERX BIOPHARMS INC (RGRX) | 343 | 0.00% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Celcuity Inc.'s median reaction calculated?
Every labeled CELC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 354 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of CELC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CELC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.